Skip to Content

Cysteamine for Cystinosis

Cysteamine bitartrate (Cystagon - Mylan), an orphan drug, has been approved by the US Food and Drug Administration for oral treatment of nephropathic cystinosis, an autosomal recessive metabolic disorder that affects only a few hundred people in the USA (WA Gahl et al, in The Metabolic Basis of Inherited Disease, 7th ed., CR Scriver et al, eds, New York:McGraw-Hill, 1995, p 3763)....
Cannot Access - We are sorry, but you cannot access the requested article.
login now
login now
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Cysteamine for Cystinosis
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 938
Article Code: 938c
Date: December 23, 1994
Volume: 36
Page: 118

 Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article.
 Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article.